Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Team with CapitalBio on MDx Applications

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche Diagnostics today said that it has signed a memorandum of understanding to collaborate with China's CapitalBio on developing molecular diagnostics applications and technologies to serve unmet needs of researchers worldwide.

Specifically, the alliance aims to further develop microarray technologies and complementary products for molecular diagnostics applications. The initial focus will be on enhancing and automating the Roche NimbleGen microarray workflow for preventive and personalized diagnostics, said Roche.

The firms also plan to cooperate on education efforts on the benefits and use of molecular diagnostics that exploit technologies such as microarrays and Roche 454 Life Sciences' next-generation sequencing products in China and international markets. According to Fatt-Heng Wong, GM of Roche Diagnostics Shanghai, the firms also plan to cooperate in marketing products in the greater China and international markets.

Financial and other terms of the alliance were not disclosed.

CapitalBio already serves as certified service provider of NimbleGen products. The firm operates a medical testing lab in Chengdu and a microarray genomics service facility at its headquarters in Beijing.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.